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It was initially reported that levels of polychlorinated biphenyls (PCBs) or p,p'-DDE were elevated
in breast cancer patients (serum or tissue) versus controls. These results, coupled with reports
that selected environmental estrogens decreased 17J,Bestradiol (E2) 2-hydroxylase activity and
increased the ratio of 16a-hydroxyestrone/2-hydroxyestrone metabolites in MCF-7 human breast
cancer cells, have led to the hypothesis that xenoestrogens are a preventable cause of breast
cancer. More recent studies and analysis of organochlorine levels in breast cancer patients versus
controls show that these contaminants are not elevated in the latter group. Moreover,
occupational exposure to relatively high levels of PCBs and DDT/DDE are not associated with an
increased incidence of breast cancer. A reexamination of the radiometric E2 2-hydroxylase assay
in MCF-7 cells with diverse estrogens, antiestrogens, and carcinogens showed that the
mammary carcinogen benzo[a]pyrene induced this response and the antiestrogen ICI 164,384
decreased E2 2-hydroxylase activity. Thus, E2 2-hydroxylase activity and the 16a-hydroxyestrone/
2-hydroxyestrone metabolite ratio in MCF-7 cells does not predict xenoestrogens or mammary
carcinogens. Environ Health Perspect 105(Suppl 3):675-678 (1997)
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Background
Several studies have shown that a number
ofindustrial compounds exhibit estrogenic
activity and these indude various phenols
and structurally diverse organochlorine
environmental contaminants such as poly-
chlorinated biphenyls (PCBs), hydroxylated
PCBs, kepone, methoxychlor, DDT, DDE,
and related compounds (1-7). Moreover,
some ofthe persistent organochlorine envi-
ronmental contaminants have been linked
to reproductive failures in some wildlife
species and inlaboratory animal studies (8).
These observations have led to the hypothe-
sis that endocrine-disrupting environmental
contaminants may be responsible for
decreased male reproductive capacity in
humans, including a possible worldwide
decrease in male sperm counts over the past
This paper was presented in part at the Workshop on
Hormones, Hormone Metabolism, Environment, and
Breast Cancer held 28-29 September 1995 in New
Orleans, Louisiana. Manuscript received at EHP 18
June 1996; manuscript accepted 11 September 1996.
Address correspondence to Dr. S.H. Safe,
Veterinary Physiology and Pharmacology, Texas A&M
University, College Station, TX 77843-4466.
Telephone: (409) 845-5988. Fax: (409) 862-4929.
E-mail: ssafe@cvm.tamu.edu
Abbreviations used: DMBA, dimethylbenz[alanthra-
cene; E1, estrone; E2, 17,B-estradiol; ER, estrogen
receptor; 13C, indole-3-carbinol; PCBs, polychlorinated
biphenyls.
50 years (9,10). Carlsen and co-workers
(11) reported that metaanalysis ofselected
sperm count studies showed a precipitous
decline and this was supported by reports
from Paris, Sweden, and Scotland (12-14).
However, recent studies have also reported
that during the past 20 to 25 years, sperm
counts in NewYork, Minnesota, California,
Washington, and Toulouse, France, have
remained constant (15-17). These results
show remarkable regional variations in
sperm counts with the current high values
in New York being comparable to those
previously reported in the 1950s through
1960s (18). These regional variations sug-
gest that metaanalysis may not be appro-
priate for analysis of temporal trends in
sperm counts; moreover, the variability in
these trends suggests that decreased sperm
counts may be a local/regional problem
and not a global calamity. Another impor-
tant component ofthe endocrine disruptor
hypothesis is that xenoestrogens may also
play a role in the observed increased inci-
dence ofbreast cancer in the United States
and many other countries (19,20). The
Workshop on Hormones, Hormone
Metabolism, and Breast Cancer focused on
several aspects ofthis question and this
paper will address issues raised by some of
the invited speakers.
Role ofOrganochlorine
Xenoestrogens in
Breast Cancer
Several studies have demonstrated that the
overall cumulative exposure ofwomen to
estrogens results in an increased risk for
breast cancer. Some ofthese risk factors
include age at menarche, age at first birth,
age at natural menopause, parity, and obe-
sity (postmenopausal) (21). Dietary and
lifestyle factors also play a role in develop-
ment of breast cancer and this is sup-
ported, in part, by the increased incidence
of this disease in Oriental women (low
incidence) who migrate to the United
States. Davis and co-workers (19,20) have
also hypothesized that changes in exposures
to xenoestrogenic substances may partly
account for recent trends in breast cancer.
The potential role oforganochlorine
compounds as etiologic agents in breast
cancer was suggested by results of case-
control studies that showed that a) levels
ofDDT and related metabolites (primarily
p,p'-DDE) were higher in serum or tumors
of breast cancer patients versus controls
(22); b) PCB levels were higher in mam-
mary adipose tissue of breast cancer
patients in Connecticut than in controls
(23); c) DDE levels were higher in mam-
mary adipose tissue ofestrogen receptor-
positive breast cancer patients compared to
controls (24); and d) [-hexachlorocyclo-
hexane levels in tumors were higher than in
controls (25). All of these studies con-
tained 58 or fewer individuals in their
patient groups. Krieger and co-workers
(26) used a cohort of 150 breast cancer
patients and 150 control subjects in
California and showed that there was not a
significant difference in serum organochlo-
rine levels in the two groups. There are sev-
eral ongoing studies that are investigating
levels of organochlorine compounds in
breast cancer patients and control groups;
however, at present the following points
should be considered:
Analysis ofall the available data indi-
cates that organochlorine levels are not
significantly higher in breast cancer
patients than in controls (27-29). In
their review ofthe data for breast and
endometrial cancers, Adami and co-
workers (29) stated that "available data
do not indicate that organochlorines
will affect the risk ofthese two cancers
in any but the most unusual situation."
The overall ratio of means (cases/
controls) for DDE and PCBs in all the
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studies were 1.08 and 1.03 and were
not significandy elevated (29).
Adami and co-workers (29) also
reviewed the breast cancer incidence in
women occupationally exposed to
PCBs; their summary analysis reported
an overall observed/expected ratio of
0.84, indicating that among women
highly exposed to PCBs, there was not
an increased incidence ofbreast cancer.
Moreover, high exposure to DDT has
not been associated with an increased
risk ofbreast cancer (28,29).
* Wolff (30) recently pointed out that
adipose tissue levels ofDDT and related
metabolites (and PCBs) have been
declining since 1965 and similar
decreases in breast milk DDE levels
have been reported in Scandinavian
countries (31). These declines corre-
spond to the restricted use and ultimate
ban of DDT in most industrialized
countries, even though there is continued
use ofthis pesticide for insect control in
less-developed nations. Nevertheless, the
marked decline in DDE levels and the
parallel increased incidence ofbreast
cancer does not support an etiologic role
for DDT in this disease.
* Several studies have demonstrated the
estrogenic activity of DDT and related
compounds as well as some PCBs and
hydroxylated PCBs in breast cancer
cells and in the rodent uterus. However,
it is also true that other persistent chlo-
rinated pollutants including some PCB
congeners, polychlorinated dibenzofu-
rans and dibenzo-p-dioxins, exhibit
antiestrogenic activities in the same
bioassay (32). Safe (33) has suggested
that in terms ofdietary intake oforgano-
chlorine pollutants, the overall intake of
antiestrogen equivalents was greater
than estrogen equivalents in the diet.
This is an issue that should be further
investigated. In their article hypothesiz-
ing that xenoestrogens may play a role
in breast cancer, Davis and co-workers
(19) pointed out that DDT accelerated
2-acetamidophenanthrene-induced
mammary gland tumors in the male
Sprague-Dawley rat (34). This is not a
widely used animal model or carcino-
gen for investigating development and
growth ofbreast cancer in women. In
contrast, they failed to point out a study
by Silinskas and Okey (35), who used
the 7,12-dimethylbenz[a]anthracene
(DMBA) model to show that DDT
protected against mammary tumor
formation in female rats.
These results do not support the
hypothesis that organochlorine xenoestro-
gens are etiologic agents for breast cancer.
However, the studies that have reported ele-
vated levels ofPCBs, DDE, and polybromi-
nated biphenyls (36) in breast cancer
patients should be further investigated.
Persistent halogenated aromatic com-
pounds preferentially bioconcentrate in
fatty tissue and these compounds may be a
biomarker ofimportant dietary factors that
playa role in mammary carcinogenesis.
Good and Bad Estrogens?
Bradlow and co-workers (19,20,37) have
hypothesized a possible role for the
2-hydroxy and 16a-hydroxy metabolites of
17,-estradiol (E2) and estrone (E1) in
the development of breast cancer. 16a-
Hydroxy-El levels were elevated in strains
ofmice susceptible to mammary cancer and
levels were also elevated in breast cancer
patients (38,39). Osborne and co-workers
(40) also reported that E2 16a-hydroxylase
activity was higher in mammary terminal
duct lobular units from breast cancer
patients than in patients undergoing reduc-
tive mammoplasty. Swaneck and Fishman
(41) also reported that 16a-hydroxy-E,
covalently binds to the estrogen receptor
(ER) in MCF-7 cells and suggested that
this may play a role in malignant transfor-
mation of mammary tissue. In contrast,
increased levels ofE2 2-hydroxylase activity
are associated with protection from mam-
mary cancer in both animal models and in
humans; moreover, 2-hydroxy-E2 is ele-
vated in animal models and humans
exposed to indole-3-carbinol (I3C) and
related compounds that are protective
against mammary cancer (38,41-43). The
concept of good (2-hydroxy-EI/E2) and
bad (16a-hydroxy-EI/E2) estrogens was
recently expanded by Bradlow and co-
workers (37), who proposed that the 16a-
hydroxy-E1/2-hydroxy-E, metabolite ratio
in MCF-7 cells treated with E2 (radiola-
beled with [3H] at C-2 or C-16) was pre-
dictive for mammary carcinogens. The
compounds used in their study included
the following: I3C, an anticarcinogen;
DMBA, a mammary carcinogen; atrazine,
a putative estrogen that enhances time-to-
tumor formation in one rat strain; and sev-
eral organochlorine pesticides that were
either weakly estrogenic or indirectly asso-
ciated with elevated breast cancer levels in
some studies (y-hexachlorocyclohexane,
2,2',4,4',5-pentachlorobiphenyl, kepone,
p,p'-DDE, p,p'-DDT, o,p'-DDE, o,p'-
DDT, endosulfan-1, endosulfan-2, and
p,p'-DDethane). Treatment of MCF-7
cells with 10 iM I3C increased 2-hydroxy-
lation and decreased 16ax-hydroxylation of
E2, whereas DMBA, atrazine, and the
organochlorine pesticides decreased E2
2-hydroxylase and increased 16or-hydroxy-
lase activities using a radiometric assay pro-
cedure. The predictive value of these
hydroxylase activities and their ratios pre-
sented some problems based on results of
other studies and these are indicated below.
* The induction ofCYPlAI-dependent E2
2-hydroxylase activity by 10 jiM I3C is
inconsistent with previous studies, which
report that I3C induces CYPlAI gene
expression or immunoreactive protein at
concentrations >125 pM (44,45).
* Recent studies in this laboratory show
that 10 pM I3C acts as a partial aryl
hydrocarbon receptor antagonist (45).
* Most of the organochlorine pesticides
included in this study are not active as
inducers in cancer cell lines and their
activity as inducers or inhibitors ofE2
16a- or 2-hydroxylase activity has not
previously been reported.
Atrazine was included in the list ofcom-
pounds due to its designation as an estro-
genic compound (20); however, recent
studies have shown that this compound is
not estrogenic in several diagnostic bio-
assays including the E-SCREEN (7,46).
Therefore, research in this laboratory (47)
has reinvestigated the effects of several
model compounds as inducers of E2
2-hydroxylase activity in MCF-7 cells using
the radiometric assay. The results obtained
for I3C were similar to those reported by
Bradlow and co-workers (37); namely, a 2-
to 4-fold induction ofE2 2-hydroxylase was
observed 48 hr after treatment with I3C.
However, E2 2-hydroxylase activitywas also
induced after treatment with 13C for only 2
hr, indicating that the induced response
was due, in part, to an in vitro effect and
not an induction response. Similar results
were obtained for atrazine and DMBA
which caused decreased E2 2-hydroxylation
in MCF-7 cells after incubation for 2 or 48
hr. Moreover, it was also shown that
benzo[a]pyrene, a mammary carcinogen,
induced E2 2-hydroxylase activity and this
was consistent with previous reports show-
ing that this compound induced CYPlAl-
dependent activity in MCF-7 cells (48). In
contrast, two potent antiestrogens, ICI
164,384 and ICI 182,780, decreased E2
2-hydroxylase activity in MCF-7 cells after
incubation for 48 hr. These results indicate
that a mammary carcinogen can induce E2
2-hydroxylase activity whereas this response
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is inhibited by some antiestrogens that are
anticarcinogens.
Summary
Although overall exposure to estrogens is a
known risk factor for development ofbreast
cancer, current data do not support a role of
organochlorine compounds such as PCBs
and DDE as etiologic agents. It is possible
that there are other unknown sources of
human exposure to xenoestrogens; however,
their potential impact must be considered
along with relatively high dietary intakes of
natural estrogenic (e.g., bioflavonoids) and
antiestrogenic (e.g., I3C) substances in food
(33). The results ofrecent studies in the lab-
oratory suggest that the radiometric E2
2-hydroxylase activity in MCF-7 cells is not
a consistent predictor ofmammary carcino-
gens; however, this does not preclude the
use ofthe 16a-hydroxy-El/2-hydroxy-E,
ratio for predicting cancer risk in other in
vitroor in vivobioassays. The significance of
16a- and2-hydroxy-E2/Ej metabolite ratios
as prognostic indicators for mammary
cancer is controversial (49) and also requires
further investigation.
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